Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | FAAH | O00519 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL509080 | 0.79 | CNR1 (0.30) | — | |
| SCHEMBL9067321 | 0.79 | MAPT (0.34) | MEN1FAAHTP53CYP1A2CYP3A4 | |
| SCHEMBL8501219 | 0.76 | CHRM2 (0.39) | CYP2C19ALOX15 | |
| SCHEMBL3689148 | 0.73 | SOAT2 (0.30) | SOAT1 | |
| SCHEMBL1416181 | 0.73 | FAAH (0.58) | MEN1FAAHTP53CYP1A2CYP3A4 | |
| SCHEMBL1416177 | 0.73 | FAAH (0.58) | MEN1FAAHTP53CYP1A2CYP3A4 | |
| SCHEMBL28080510 | 0.72 | ALOX15 (0.39) | MEN1FAAHTP53CYP1A2CYP3A4 | |
| SCHEMBL3761063 | 0.71 | — | — | |
| SCHEMBL2121970 | 0.71 | ALDH1A1 (0.31) | CYP3A4CYP2C19 | |
| SCHEMBL1416727 | 0.70 | ALOX15 (0.46) | MEN1FAAHTP53CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111919141-A | Silicone hydrogel contact lenses | 爱尔康公司 | 2020-11-10 | — | — | CN | disclosed |
| WO-2009085642-A1 | TRIMETHYLSILYL-CAPPED POLYSILOXANE MACROMONOMERS CONTAINING POLAR FLUORINATED SIDE-CHAINS | BAUSCH & LOMB INCORPORATED (US) | 2009-07-09 | — | — | WO | disclosed |
| US-20090168013-A1 | Trimethylsilyl-Capped Polysiloxane Macromonomers Containing Polar Fluorinated Side-Chains | BAUSCH & LOMB INCORPORATED | 2009-07-02 | — | — | US | disclosed |
| US-5321108-A | Improving solubility of unsaturated siloxane monomers in hydrophilic monomer | BAUSCH & LOMB INCORPORATED (US) | 1994-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090168013-A1 | Trimethylsilyl-Capped Polysiloxane Macromonomers Containing Polar Fluorinated Side-Chains | VCL, PCNA, MLEC | MEN1 2050/4885FAAH 3114/4885TP53 3040/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.